摘要
目的:比较国产与进口多西紫杉醇应用于乳腺癌新辅助化疗的疗效和安全性。方法:收集2000年1月至2005年12月应用含国产多西紫杉醇(艾素)与进口多西紫杉醇(泰索帝)方案进行新辅助化疗的69例女性乳腺癌患者的临床资料,对近期疗效和不良反应进行回顾性分析。化疗方案为TAC(多西紫杉醇+表阿霉素+环磷酰胺),28天为1个周期,化疗2周期后手术,国产与进口组患者分别为35和34例。结果:所有患者均完成2个周期化疗,两组均无疾病进展病例。其中国产组3例(8.6%)获得完全缓解(CR),26例(74.3%)部分缓解(PR),6例(17.1%)病变稳定(SD);进口组CR4例(11.%),PR25例(73.5%),SD5例(14.7%)。国产与进口组总有效率分别为82.9%和85.3%,两组比较差异无显著性(P>0.05)。两组均无不能耐受不良反应而退出治疗病例。不良反应主要有骨髓抑制、胃肠道反应、脱发、神经毒性和过敏反应等。国产与进口组粒细胞减少发生率均为100%,III度以上发生率分别为38.6%(27/70)、54.4%(38/68),两组相比有显著性差异(P<0.05)。其余不良反应两组相似。结论:国产多西紫杉醇应用于乳腺癌新辅助化疗,疗效确切,不良反应容易处理,与进口多西紫杉醇相似,且价格远低于进口多西紫杉醇,值得推广。
Objective：To evaluate efficacy and safety of domestic and imported docetaxel regimens as neoadjuvant chemotherapy for local advanced breast cancer.Methods：From 2000 to 2005,69 female patients with local advanced cancer were treated with domestic docetaxel or imported docetaxel regimen.Patients received docetaxel 70 mg/m2 on day1;epirubincin（EPI） 50 mg/m2 on day1,8;cyclophosphamide（CTX） 500 mg/m2 on day1,8 for 2 cycles every 28 days.Accroding to the effect standard and toxic grading standard suggested by WHO efficacy and safety were evaluated after 2 cycles of neoadjuvant chemotherapy.Results：All patients completed two cycles of chemotherapy,and the efficacy and side effects could be evaluated.There was no disease progressive in two groups.The overall response rates in domestic group was 82.9%（29/35）,including 3 complete response cases,26 partial response cases and 6 stable disease cases.The overall response rate in imported groups was 85.3%（29/34）,including 4 complete response cases,25 partial response cases and 5 stable disease cases.There was no significantly difference（P〉0.05） in two groups.The frequent side effects included myelosuppression,gastroenteric reactions,alopecia,neutropenia and allergic response.The incidence of granulopenia in two groups were 100%,III-IV grade incidence in the domestic group was lower than that in the imported group,P〈0.05.Other side effects between two groups were similar.Conclusion：Domestic docetaxel regimen is effective and has acceptable tolerance for neoadjuvant chemotherapy in local advanced breast cancer,the cost is much lower than imported docetaxel.So domestic docetaxel regimen should be recommended.
出处
《现代肿瘤医学》
CAS
2007年第10期1423-1426,共4页
Journal of Modern Oncology
